X4 PHARMACEUTICALS, INC Other Noncash Income (Expense)
X4 PHARMACEUTICALS, INC (XFOR) reported Other Noncash Income (Expense) of $165.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC other noncash income (expense) for the quarter ending 2026-06-30 was $59.00K.
- X4 PHARMACEUTICALS, INC other noncash income (expense) for the quarter ending 2026-03-31 was $106.00K, a 38.73% decline year-over-year.
- X4 PHARMACEUTICALS, INC other noncash income (expense) for the quarter ending 2025-12-31 was $205.00K, a 51.85% increase year-over-year.
- X4 PHARMACEUTICALS, INC other noncash income (expense) for the quarter ending 2025-09-30 was $152.00K, a 31.84% decline year-over-year.
- X4 PHARMACEUTICALS, INC other noncash income (expense) for fiscal 2025 was $161.00K, a 74.80% decline from fiscal 2024.
- X4 PHARMACEUTICALS, INC other noncash income (expense) for fiscal 2024 was $639.00K, a 181.50% increase from fiscal 2023.
- X4 PHARMACEUTICALS, INC other noncash income (expense) for fiscal 2023 was $227.00K.
- X4 PHARMACEUTICALS, INC other noncash income (expense) for fiscal 2022 was -$37.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $165.00K 10-Q · filed 2026-08-06 | $370.00K derived: sum of 3 quarters · filed 2026-08-06 | $522.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $106.00K 10-Q · filed 2026-05-06 | $311.00K derived: sum of 2 quarters · filed 2026-05-06 | $463.00K derived: sum of 3 quarters · filed 2026-05-06 | $94.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $205.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $357.00K derived: sum of 2 quarters · filed 2026-03-17 | -$12.00K derived: sum of 3 quarters · filed 2026-08-06 | $161.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | $152.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$217.00K derived: sum of 2 quarters · filed 2026-08-06 | -$44.00K 10-Q · filed 2025-11-05 | $91.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$369.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$196.00K 10-Q · filed 2026-08-06 | -$61.00K derived: sum of 3 quarters · filed 2026-08-06 | $162.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $173.00K 10-Q · filed 2026-05-06 | $308.00K derived: sum of 2 quarters · filed 2026-05-06 | $531.00K derived: sum of 3 quarters · filed 2026-05-06 | $695.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $358.00K derived: sum of 2 quarters · filed 2026-03-17 | $522.00K derived: sum of 3 quarters · filed 2026-03-17 | $639.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $223.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $387.00K derived: sum of 2 quarters · filed 2025-11-05 | $504.00K 10-Q · filed 2025-11-05 | $685.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $164.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $281.00K 10-Q · filed 2025-08-08 | $462.00K derived: sum of 3 quarters · filed 2026-03-17 | $467.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $117.00K 10-Q · filed 2025-05-01 | $298.00K derived: sum of 2 quarters · filed 2026-03-17 | $303.00K derived: sum of 3 quarters · filed 2026-03-17 | $293.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $181.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $186.00K derived: sum of 2 quarters · filed 2026-03-17 | $176.00K derived: sum of 3 quarters · filed 2026-03-17 | $227.00K 10-K · filed 2026-03-17 |
| 2023-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$5.00K derived: sum of 2 quarters · filed 2024-11-13 | $46.00K 10-Q · filed 2024-11-13 | $264.00K derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $41.00K 10-Q · filed 2024-08-08 | $259.00K derived: sum of 3 quarters · filed 2025-03-26 | -$290.00K derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | $51.00K 10-Q · filed 2024-05-07 | $269.00K derived: sum of 2 quarters · filed 2025-03-26 | -$280.00K derived: sum of 3 quarters · filed 2025-03-26 | -$106.00K derived: sum of 4 quarters · filed 2025-03-26 |
| 2022-12-31 | $218.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$331.00K derived: sum of 2 quarters · filed 2025-03-26 | -$157.00K derived: sum of 3 quarters · filed 2025-03-26 | -$37.00K 10-K · filed 2025-03-26 |
| 2022-09-30 | -$549.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$375.00K derived: sum of 2 quarters · filed 2023-11-09 | -$255.00K 10-Q · filed 2023-11-09 | -$309.00K derived: sum of 4 quarters · filed 2024-03-21 |
| 2022-06-30 | $174.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $294.00K 10-Q · filed 2023-08-10 | $240.00K derived: sum of 3 quarters · filed 2024-03-21 | -$24.00K derived: sum of 4 quarters · filed 2024-03-21 |
| 2022-03-31 | $120.00K 10-Q · filed 2023-05-04 | $66.00K derived: sum of 2 quarters · filed 2024-03-21 | -$198.00K derived: sum of 3 quarters · filed 2024-03-21 | -$118.00K derived: sum of 4 quarters · filed 2024-03-21 |
| 2021-12-31 | -$54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$318.00K derived: sum of 2 quarters · filed 2024-03-21 | -$238.00K derived: sum of 3 quarters · filed 2024-03-21 | -$337.00K 10-K · filed 2024-03-21 |
| 2021-09-30 | -$264.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$184.00K derived: sum of 2 quarters · filed 2022-11-03 | -$283.00K 10-Q · filed 2022-11-03 | -$89.00K derived: sum of 4 quarters · filed 2023-03-21 |
| 2021-06-30 | $80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$19.00K 10-Q · filed 2022-08-04 | $175.00K derived: sum of 3 quarters · filed 2023-03-21 | $363.00K derived: sum of 4 quarters · filed 2023-03-21 |
| 2021-03-31 | -$99.00K 10-Q · filed 2022-05-12 | $95.00K derived: sum of 2 quarters · filed 2023-03-21 | $283.00K derived: sum of 3 quarters · filed 2023-03-21 | $384.00K derived: sum of 4 quarters · filed 2023-03-21 |
| 2020-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $382.00K derived: sum of 2 quarters · filed 2023-03-21 | $483.00K derived: sum of 3 quarters · filed 2023-03-21 | $413.00K 10-K · filed 2023-03-21 |
| 2020-09-30 | $188.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $289.00K derived: sum of 2 quarters · filed 2021-11-04 | $219.00K 10-Q · filed 2021-11-04 | $219.00K derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-06-30 | $101.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $31.00K 10-Q · filed 2021-08-03 | $31.00K derived: sum of 3 quarters · filed 2022-03-17 | $31.00K derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-03-31 | -$70.00K 10-Q · filed 2021-05-06 | -$70.00K derived: sum of 2 quarters · filed 2022-03-17 | -$70.00K derived: sum of 3 quarters · filed 2022-03-17 | -$70.00K derived: sum of 4 quarters · filed 2022-03-17 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $0.00 derived: sum of 3 quarters · filed 2022-03-17 | $0.00 10-K · filed 2022-03-17 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $0.00 10-Q · filed 2020-08-04 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |